Anti-PD-1 Alone Produces Durable Responses in Relapsed/Refractory PMBCL

(MedPage Today) -- Credit: CoRus13 Single-agent pembrolizumab (Keytruda) produced durable responses and encouraging survival in patients with relapsed/refractory (R/R) primary mediastinal B-cell lymphoma (PMBCL), according to long-term follow...
Source: MedPage Today Hematology/Oncology - Category: Hematology Source Type: news